This is the authors' abstract. We don't add key points for this paper.
Escherichia coli ( E. coli ) O157:H7, a highly virulent foodborne pathogen, poses a substantial threat to public and veterinary health. Its ability to form robust biofilms significantly amplifies virulence and confers resistance to conventional antibiotics, often leading to therapeutic failure. In this study, we employed a genetically engineered LuxS-eGFP reporter strain to screen for compounds targeting the LuxS/AI-2 quorum sensing (QS) system—a key regulator of biofilm formation. Our investigation identified Isoferulic Acid (IFA) as a potent inhibitor of this pathway. IFA effectively suppressed de novo biofilm formation in E. coli O157:H7 without exerting bactericidal effects or impairing general metabolic activity, and it also demonstrated efficacy in dispersing pre-established mature biofilms. Furthermore, we established a novel combinatorial therapeutic strategy by integrating IFA with the antibiotic sodium fosfomycin. This combination exhibited a marked synergistic effect, significantly enhancing antibacterial efficacy against E. coli both in vitro and in vivo . These results substantiate that IFA possesses significant antibiofilm activity and a unique capacity to potentiate antibiotic action, thereby offering a promising new avenue for combating recalcitrant E. coli infections.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: